Denifanstat for MASH: New Outlook on FASN Inhibitor's Role and Combination Strategies

A new article provides an outlook on Sagimet Biosciences' oral FASN inhibitor denifanstat for MASH (Metabolic Dysfunction-Associated Steatohepatitis), discussing its mechanism, past Phase 2b FASCINATE-2 trial data, and future Phase 3 outlook. While the Phase 3 monotherapy program was withdrawn, a combination strategy with resmetirom for F4 cirrhosis is being explored.